Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...

University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...

Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits of ...

Researchers released new clinical guidelines for treating restless legs syndrome (RLS), emphasizing patient-centered care and ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Drug therapy: A new study, recently published ... medication Mounjaro and weight loss treatment Zepbound – helps reduce ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

Army veteran Bryan Vadney used to love life, was being active, spent time with family and friends, and took part in his ...

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea. In the OSPREY study ... market-moving breaking financial ...